LakeShore Biopharma Completes Going-Private Merger, Shares to Be Delisted
LSBCF has more than doubled off its 52-week low of $0.028.
Summary
LakeShore Biopharma has completed its going-private merger, effective June 24, 2026, resulting in the company becoming a private entity and its shares being delisted from public trading.
Key Events · M&A and Partnerships · LSBCF
-
Merger Completed
The going-private merger became effective on June 24, 2026, making LakeShore Biopharma a wholly-owned subsidiary of Oceanpine Skyline Inc.
-
Shareholder Payout
Public shareholders will receive $0.066 in cash for each ordinary share.
-
Delisting Imminent
The company's trading symbols are expected to be removed by FINRA, and the shares will cease to be quoted on the OTC Pink tier.
-
Reporting Obligations End
LakeShore Biopharma intends to suspend its reporting obligations under the Exchange Act by filing Form 15 with the SEC.
Analysis · LSBCF · Life Sciences
This filing confirms the finalization of LakeShore Biopharma's going-private merger, which became effective on June 24, 2026. As a result, the company is now a wholly-owned subsidiary of Oceanpine Skyline Inc., and its shares will cease to be quoted on the OTC Pink tier. Public shareholders will receive $0.066 per share, marking the end of the company's public trading. This is a definitive, thesis-altering event for investors.
At the time of this filing, LSBCF was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $0.03 to $2.80. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.